PSTV vs. XAIR, PTHL, CODX, BSGM, FEMY, NXGL, VVOS, PETV, NRXS, and NEPH
Should you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Beyond Air (XAIR), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Co-Diagnostics (CODX), BioSig Technologies (BSGM), Femasys (FEMY), NEXGEL (NXGL), Vivos Therapeutics (VVOS), PetVivo (PETV), NeurAxis (NRXS), and Nephros (NEPH). These companies are all part of the "medical equipment" industry.
Plus Therapeutics vs.
Plus Therapeutics (NASDAQ:PSTV) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 20.1% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Beyond Air had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 1 mentions for Beyond Air and 0 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Beyond Air's score of -0.36 indicating that Plus Therapeutics is being referred to more favorably in the media.
Plus Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.
Plus Therapeutics has higher revenue and earnings than Beyond Air. Plus Therapeutics is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Plus Therapeutics has a net margin of -225.07% compared to Beyond Air's net margin of -2,369.17%. Plus Therapeutics' return on equity of 0.00% beat Beyond Air's return on equity.
Plus Therapeutics presently has a consensus target price of $13.50, suggesting a potential upside of 988.71%. Beyond Air has a consensus target price of $3.67, suggesting a potential upside of 735.42%. Given Plus Therapeutics' higher probable upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Beyond Air.
Plus Therapeutics received 20 more outperform votes than Beyond Air when rated by MarketBeat users. However, 69.57% of users gave Beyond Air an outperform vote while only 62.39% of users gave Plus Therapeutics an outperform vote.
Summary
Beyond Air beats Plus Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Plus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Plus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PSTV) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PSTV Stock Alerts